_biotech-boom-ahead-in-2024-top-jefferies-analyst-predicts-on-heels-of-bristol-meyers-karuna-deal-preview-1.jpg "Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal from siwa biotech corp Video Screenshot Preview 1")
Gallery_biotech-boom-ahead-in-2024-top-jefferies-analyst-predicts-on-heels-of-bristol-meyers-karuna-deal-preview-3.jpg "Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal from siwa biotech corp Video Screenshot Preview 3")
Gallery_biotech-boom-ahead-in-2024-top-jefferies-analyst-predicts-on-heels-of-bristol-meyers-karuna-deal-preview-hqdefault.jpg "Biotech boom ahead in 2024, top Jefferies analyst predicts on heels of Bristol Meyers-Karuna deal from siwa biotech corp Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 5 minutes 52 seconds
👁 View: 20.3K times
Play Audio:👁 View: 20.3K times
Description:
CNBC Television
CNBC Television
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_what-it-takes-to-build-a-364-8-billion-biotech-company-124-forbes.webp "Forbes")
_2023-and-beyond-the-future-of-biotech.webp "Nasdaq")
_cathie-wood39s-ark-invest39s-third-largest-holding-is-this-little-known-biotech-company-harnessing-ai-for-drug-treatment.webp "Cathie Wood's ARK Invest has been buying shares of Recursion Pharmaceuticals, a biotech company using AI to speed up drug discovery. It is now the third-largest holding in her ARK Genomic Revolution ETF. Recursion has developed an AI-powered operating system that conducts up to 2.2 million weekly experiments to test drug candidates in an automated laboratory, advancing only the most promising compounds to clinical trials. Using AI this way could allow Recursion to launch drugs faster than competitors and license its OS to other companies, building a network effect that improves its algorithm over time.")
_cramer-this-biotech-stock-could-be-worth-over-36100-billion-on-an-fda-approval.webp "CNBC Television")
⏲ 5 minutes 19 seconds 👁 197.9K
_what-it-takes-to-build-a-364-8-billion-biotech-company-124-forbes.jpg)
_2023-and-beyond-the-future-of-biotech.jpg)
_cathie-wood39s-ark-invest39s-third-largest-holding-is-this-little-known-biotech-company-harnessing-ai-for-drug-treatment.jpg)
_cramer-this-biotech-stock-could-be-worth-over-36100-billion-on-an-fda-approval.jpg)
![[+]](/images/menu.gif){kind=small}